Publication | Closed Access

First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial

Hematological MalignancyLymphoid NeoplasiaOncologyImmunologyHematologyFirst-line ChemoimmunotherapyImmune Checkpoint InhibitorPharmacotherapyNon-inferiority TrialImmunotherapyMedicinePhase 3